| Literature DB >> 35734586 |
Zhaonan Sun1, Yingpu Cui2,3, Chunru Xu4, Yanfei Yu4, Chao Han5, Xiang Liu1, Zhiyong Lin1, Xiangpeng Wang6, Changxin Li6, Xiaodong Zhang1, Xiaoying Wang1.
Abstract
Objective: To develop radiomics models to predict inferior vena cava (IVC) wall invasion by tumor thrombus (TT) in patients with renal cell carcinoma (RCC).Entities:
Keywords: carcinoma; inferior; magnetic resonance imaging; radiomics; renal cell; thrombus; vena cava
Year: 2022 PMID: 35734586 PMCID: PMC9207178 DOI: 10.3389/fonc.2022.863534
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 5.738
Figure 1Patient enrollment folw chart. RCC, renal cell carcinoma; TT, tumor thrombus; IVC, inferior vena cava. Other renal mass include four angiomyolipoma, one inflammatory myofibroblastic tumor, one synovial sarcoma, one malignant solitary fibrous tumors, and one primitive neuroectodermal tumor.
Figure 2(A) Axial fat-suppression T2-weighted image (fsT2WI) in a 68-year old man with a clear cell renal cell carcinoma (cRCC) and an inferior vena cava (IVC) tumor thrombus (TT) with wall invasion. Subjective features of complete occlusion of the IVC lumen, the irregular margin of the TT (arrow), thickened IVC wall (arrow and triangle), and abnormal signal of the IVC wall (arrow) can be found. (B) Axial fsT2WI in a 76-year old woman with cRCC and a TT in IVC without wall invasion. The crescent-shaped black areas on the laterodorsal aspect of IVC stand for flow void (star). (C–F) Examples for annotation of IVC and TT. The red represents the mask of the IVC, and the green represents the mask of the TT. The three-dimensional (3D) volumes of interest (VOIs) are at the upper right corner.
Demographic and clinical characteristics in the training cohort and validation cohort.
| Training cohort (n=64) | Validation cohort (n=27) |
| |||||
|---|---|---|---|---|---|---|---|
| Invasion (n=31) | No invasion (n=33) |
| Invasion (n=13) | No invasion (n=14) |
| ||
| Age, mean ± SD (years) | 52.5 ± 11.3 | 55.1 ± 10.7 | 0.754 | 52.1 ± 13.7 | 58.2 ± 9.0 | 0.130 | 0.686 |
| Male, n (%) | 29 (93.5) | 20 (60.6) | 0.002 | 20 | 12 | 0.587 | 0.255 |
| Mean kg/m2 body mass index (range) | 24.8 (21.1-28.8) | 25.1 (17.5-28.7) | 0.734 | 24.0 (21.0-25.8) | 24.5 (21.0-28.7) | 0.807 | 0.026 |
| Right kidney involvement, n (%) | 17 54.8) | 26 (78.8) | 0.043 | 10 (76.9) | 10 (71.4) | 0.749 | 0.924 |
| Histopathologic diagnoses, n (%) | 26 (83.9) | 25 (75.8) | 0.280 | 11 (84.6) | 13 (92.9) | 0.563 | 0.352 |
| Mayo classification#, n (%) | 0 (0.0) | 7 (21.2) | 0.001 | 3 (23.1) | 4 (28.6) | 0.149 | 0.058 |
| Fuhrman Grade, n (%) | 1 (3.2) | 0 (0.0) | 0.214 | 0 (0.0) | 0 (0.0) | 0.224 | 0.838 |
| Rhabdomyolysis or sarcomatoid degeneration, n (%) | 7 (22.6) | 4 (12.1) | 0.271 | 3 (23.1) | 2 (14.3) | 0.564 | 0.295 |
| 3.0-Tesla scanner, n(%) | 15 (48.4) | 23 (69.7) | 0.214 | 7(53.8) | 7(50.0) | 0.867 | 0.510 |
| Craniocaudal extent, mean ± SD (cm) | 7.59 ± 3.47 | 5.10 [2.80,7.65] | 0.024* | 9.47 ± 4.23 | 3.61 ± 2.88 | <0.001 | 0.599 |
| Maximal anterior-posterior diameter of RV, mean ± SD (cm) | 1.78 ± 0.57 | 1.712 ± 0.52 | 0.633 | 1.80 [1.60, 2.10] | 1.63 ± 0.68 | 0.189‡ | 0.686 |
| Maximal superior-inferior diameter of RV, mean ± SD (cm) | 1.85 ± 0.49 | 1.867 ± 0.62 | 0.915 | 1.90 [1.75, 2.70] | 1.79 ± 0.75 | 0.253 | 0.484 |
| Maximal anterior-posterior diameter of IVC, mean ± SD (cm) | 3.13 ± 1.041 | 2.358 ± 1.04 | 0.004* | 3.31 ± 0.93 | 1.60 [1.12, 3.23] | 0.006 | 0.758 |
| Maximal coronal diameter of IVC, mean ± SD (cm) | 3.797 ± 0.97 | 2.555 ± 1.05 | <0.001* | 3.37 ± 0.89 | 2.29 ± 1.10 | 0.01 | 0.201 |
| Irregular margin of tumor thrombus, n (%) | 21 (67.7) | 4 (12.1) | <0.001* | 13 (100.0) | 2 (14.3) | <0.001 | 0.150 |
| Thickening of IVC wall, n (%) | 17 (54.8) | 7 (21.2) | <0.001* | 8 (61.5) | 1 (7.1) | 0.003 | 0.707 |
| Occlusion of the IVC wall, n (%) | 24 (77.4) | 9 (27.3) | <0.001* | 11 (84.6) | 2 (76.9) | <0.001 | 0.767 |
| Abnormal signal intensity on T2WI, n (%) | 23 (74.2) | 1 (3.0) | <0.001* | 12 (92.3) | 3 (21.4) | <0.001 | 0.538 |
Data in parentheses are percentages and data in brackets are interquartile range (IQR).
SD, standard deviation; IVC, inferior vena cava; RV, renal venous.
†Comparison between the training cohort and the validation cohort.
*Predictors included in the Binary logistic regression model (p <.05).
#The level of tumor thrombus was classified as 0 (thrombus limited to the renal vein, detected clinically or during the assessment of the pathological specimen), I (thrombus extending<2 cm above the renal vein), II (thrombus extending >2 cm above the renal vein, but below the hepatic veins), III (thrombus at the level of or above the hepatic veins but below the diaphragm), and IV (thrombus extending above the diaphragm).
Independent predictors with the radiological model for inferior vena cava wall invasion in the training cohort.
| Parameters |
| Odds ratio (95%CI) |
|
|---|---|---|---|
| Irregular margin of tumor thrombus | 1.736 | 5.673 (1.104, 29.144) | 0.038* |
| Abnormal signal intensity on T2WI | 3.949 | 51.887 (5.751, 468.142) | 0.000* |
| Constant | -1.812 | 0.163 | 0.000* |
Data in parentheses are 95% confidence interval.
β indicates the regression coefficient; CI, confidence interval.
*Represents statistically significant.
Modeling pipelines of the radiomics models and combined models.
| Radiomics model_IVC | Radiomics model_TT | Combined model_IVC | Combined model_TT | |
|---|---|---|---|---|
| Normalization | None | Z-score | None | Mean |
| Dimension reduction | PCA | PCC | PCA | PCC |
| Feature selection | KW | ANOVA | KW | ANOVA |
| Classification | XGB | DT | DT | RF |
PCA, principal component analysis; PCC, Pearson correlation coefficient; ANOVA, analysis of variance; KW, Kruskal–Wallis test; XGB, eXtreme. Gradient Boosting; DT, Decision Tree.
Figure 3ROC curves of the five models in the training cohort (A) and validation cohort (B). model 1 = radiomics model_IVC; model 2= radiomics model_TT; model 3 = combined model_IVC; model 4 = combined model_TT; model 5 = radiological model.
The five models’ performance in predicting inferior vena cava wall invasion by tumor thrombus.
| AUC (95% CI) | SEN (95% CI) | SPE (95% CI) | ACC(95% CI) | Threshold | |
|---|---|---|---|---|---|
|
| 0.931 (0.839, 0.979) | 0.867 (0.693, 0.962) | 0.912 (0.763, 0.981) | 0.875 (0.770, 0.938) | 0.484 |
|
| 0.881 (0.698, 0.973) | 0.917 (0.615, 0.998) | 0.800 (0.519, 0.957) | 0.741 (0.551, 0.871) | 0.370 |
The data shown in brackets represent the 95% confidence intervals (CIs).
model 1 = Radiomics model_IVC; model 2= Radiomics model_TT; model 3 = Combined model_IVC; model 4 = Combined model_TT; model 5 = Radiological model; AUC, area under the curve; ACC, accuracy; SEN, sensitivity; SPE, specificity.
Figure 4DeLong test of the areas under the curve (AUCs) of the 5 models in the training cohort (A) and validation cohort (B). Blue boxes represent p<0.05; Other grey boxes show p > 0.05. model 1 = radiomics model_IVC; model 2= radiomics model_TT; model 3 = combined model_IVC; model 4 = combined model_TT; model 5 = radiological model.
Figure 5Decision curve analysis (DCA) comparing the net benefits of different models in the training cohort (A) and validation cohort (B). The y-axis measures the net benefit and the x-axis indicates the threshold probability. model 1 = radiomics model_IVC; model 2= radiomics model_TT; model 3 = combined model_IVC; model 4 = combined model_TT; model 5 = radiological model.